Abstract
Although the mechanism of benefi t is unclear, data support
colchicine use in the management of recurrent pericarditis.
Imazio et al. undertook a double blind trial of adults
with acute pericarditis who were randomised to receive
colchicine 0.5 mg twice daily (patient weight > 70 kg)
or 0.5 mg daily (patient weight " 70 kg) for 3 months or
placebo.
| Original language | English |
|---|---|
| Pages (from-to) | 325-325 |
| Number of pages | 1 |
| Journal | Journal of Pharmacy Practice and Research |
| Volume | 43 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2013 |